Abeona Therapeutics (ABEO) News Today

Abeona Therapeutics Inc. (NASDAQ: ABEO) remains under pressure after its second-quarter results, as an earnings and revenue miss outweighed continued commercial progress for ZEVASKYN. Trading volume was significantly above average, suggesting heightened investor reaction to the report.

• Positive Sentiment: ZEVASKYN net revenue increased 31% sequentially to $11.4 million in Q2 2026. Abeona treated five patients during the quarter and three more in the third quarter to date, bringing total treatments since launch to 12. Abeona Therapeutics Reports Second Quarter 2026 Results and Provides Business Update
• Positive Sentiment: The company is expanding its qualified treatment center network, which now includes seven sites nationwide. Management said more centers are progressing patients through the treatment process, supporting potential future treatment and revenue growth. Abeona also reported $146.8 million in cash, cash equivalents and short-term investments at June 30, providing financial resources to support commercialization. Abeona Therapeutics Inc. Q2 2026 Earnings Call Summary
• Neutral Sentiment: Some commentary characterized the post-earnings sell-off as a potential buying opportunity, based on ZEVASKYN’s launch trajectory and Abeona’s cash position. However, the investment case remains dependent on the company’s ability to convert its treatment-center expansion into consistent commercial growth. Abeona Therapeutics Earnings Sell-Off Could Be a Buy Opportunity
• Negative Sentiment: Abeona reported a second-quarter loss of $0.35 per share, wider than the $0.23 consensus loss, while revenue of $11.38 million fell short of the $12.24 million analyst estimate. The weaker-than-expected results triggered the decline in ABEO shares and raised concerns about the pace of the commercial launch. Abeona Therapeutics Shares Fall After Q2 Miss